KR20160018451A - 캡슐화된 안타고미르를 포함하는 조성물 - Google Patents

캡슐화된 안타고미르를 포함하는 조성물 Download PDF

Info

Publication number
KR20160018451A
KR20160018451A KR1020157022914A KR20157022914A KR20160018451A KR 20160018451 A KR20160018451 A KR 20160018451A KR 1020157022914 A KR1020157022914 A KR 1020157022914A KR 20157022914 A KR20157022914 A KR 20157022914A KR 20160018451 A KR20160018451 A KR 20160018451A
Authority
KR
South Korea
Prior art keywords
mir
seq
sequence
rti
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157022914A
Other languages
English (en)
Korean (ko)
Inventor
미구엘-엔젤 아신
에울라리아 페럿
아마데오 페레즈
네우스 벨레라 고타르다
안토니오 로드리게즈 시노바스
이그나시 바르바 베르트
안토니오 다비드 가르시아-도라도 가르시아
Original Assignee
삐에르 파브르 메디까망, 쏘시에떼 아노님
펀다시오 프리바다 인스티튜트 디 레세르카 호스피탈 유니버시타리 발 헤브론
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삐에르 파브르 메디까망, 쏘시에떼 아노님, 펀다시오 프리바다 인스티튜트 디 레세르카 호스피탈 유니버시타리 발 헤브론 filed Critical 삐에르 파브르 메디까망, 쏘시에떼 아노님
Publication of KR20160018451A publication Critical patent/KR20160018451A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157022914A 2013-01-24 2014-01-23 캡슐화된 안타고미르를 포함하는 조성물 Withdrawn KR20160018451A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
EP13305082.3 2013-01-24
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
KR20160018451A true KR20160018451A (ko) 2016-02-17

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022914A Withdrawn KR20160018451A (ko) 2013-01-24 2014-01-23 캡슐화된 안타고미르를 포함하는 조성물

Country Status (16)

Country Link
US (1) US20150352055A1 (enExample)
EP (2) EP2759595B1 (enExample)
JP (1) JP2016506923A (enExample)
KR (1) KR20160018451A (enExample)
CN (1) CN105229151A (enExample)
AU (1) AU2014208419A1 (enExample)
BR (1) BR112015017650A2 (enExample)
CA (1) CA2898958A1 (enExample)
ES (2) ES2606636T3 (enExample)
HK (1) HK1219753A1 (enExample)
HU (1) HUE032125T2 (enExample)
MX (1) MX2015009323A (enExample)
PL (1) PL2759595T3 (enExample)
RU (1) RU2668794C2 (enExample)
WO (1) WO2014115103A1 (enExample)
ZA (1) ZA201505602B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
EP3939575B1 (en) * 2019-03-14 2026-07-01 M. Technique Co., Ltd. PLGA MICROPARTICLES, DELAYED-RELEASE FORMULATION OF THESE AND THEIR MANUFACTURE PROCESS
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR20120047214A (ko) * 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―ｒｎａ의 확인

Also Published As

Publication number Publication date
US20150352055A1 (en) 2015-12-10
PL2759595T3 (pl) 2017-09-29
EP2759595A1 (en) 2014-07-30
CA2898958A1 (en) 2014-07-31
JP2016506923A (ja) 2016-03-07
ES2606636T3 (es) 2017-03-24
WO2014115103A1 (en) 2014-07-31
HUE032125T2 (en) 2017-08-28
AU2014208419A1 (en) 2015-08-13
EP2948551A1 (en) 2015-12-02
CN105229151A (zh) 2016-01-06
RU2015134770A (ru) 2017-03-03
BR112015017650A2 (pt) 2017-11-21
ZA201505602B (en) 2017-05-31
ES2688160T3 (es) 2018-10-31
EP2759595B1 (en) 2016-09-14
RU2668794C2 (ru) 2018-10-02
HK1219753A1 (zh) 2017-04-13
EP2948551B1 (en) 2018-05-02
MX2015009323A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
EP2948551B1 (en) Composition comprising an encapsulated antagomir
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
EP2552454B1 (en) ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS
US12234455B2 (en) Therapeutic oligonucleotides
JP2013514372A (ja) 虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節
CN112022870A (zh) 用于治疗缺血性损伤的化合物
JP2011256204A5 (enExample)
KR20180005546A (ko) 약물이 탑재된 엑소좀 또는 나노베지클을 이용한 약학적 조성물
EP3329004B1 (en) Therapeutic oligonucleotides
JP2014533248A (ja) 神経保護の提供におけるマイクロｒｎａ１９５の使用法
JP2016506923A5 (enExample)
US20240417734A1 (en) Methods for Treating Glioblastoma by Targeting Oncomirs
JPWO2015133637A1 (ja) マイクロｒｎａ封入ナノ粒子及びその医薬用途
WO2016069717A1 (en) Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
CN102140469B (zh) 人miR-1233反义核酸及其应用
EP4634386A1 (en) Antisense oligonucleotide analogs of mir-29 and uses thereof
US20250161398A1 (en) Design and development of a novel messenger rna therapeutic to treat atherosclerosis
JP2024057599A (ja) マイクロｒｎａ２２の阻害剤
BR112018001782B1 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
BR122024021791A2 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
HK40051564A (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition, for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid